252 related articles for article (PubMed ID: 30853364)
1. Prevalence, characteristics, and risk factors of occult uterine cancer in presumed benign hysterectomy.
Desai VB; Wright JD; Gross CP; Lin H; Boscoe FP; Hutchison LM; Schwartz PE; Xu X
Am J Obstet Gynecol; 2019 Jul; 221(1):39.e1-39.e14. PubMed ID: 30853364
[TBL] [Abstract][Full Text] [Related]
2. Risk of Occult Uterine Sarcoma in Presumed Uterine Fibroids.
Cui RR; Wright JD
Clin Obstet Gynecol; 2016 Mar; 59(1):103-18. PubMed ID: 26645385
[TBL] [Abstract][Full Text] [Related]
3. Incidence of sarcoma in patients undergoing hysterectomy for benign indications: a population-based study.
Multinu F; Casarin J; Tortorella L; Huang Y; Weaver A; Angioni S; Melis GB; Mariani A; Stewart EA; Laughlin-Tommaso SK
Am J Obstet Gynecol; 2019 Feb; 220(2):179.e1-179.e10. PubMed ID: 30447212
[TBL] [Abstract][Full Text] [Related]
4. The prevalence of occult endometrial cancer in women undergoing hysterectomy for benign indications.
Parsons LHP; Pedersen R; Richardson DL; Kho KA
Eur J Obstet Gynecol Reprod Biol; 2018 Apr; 223():108-112. PubMed ID: 29518640
[TBL] [Abstract][Full Text] [Related]
5. Does fibroids surgery by endoscopy or laparotomy represent a malignancy threat?
Mettler L; Abdusattarova K; Alkatout I
Minerva Ginecol; 2017 Dec; 69(6):517-525. PubMed ID: 28696085
[TBL] [Abstract][Full Text] [Related]
6. Association Between Power Morcellation and Mortality in Women With Unexpected Uterine Cancer Undergoing Hysterectomy or Myomectomy.
Xu X; Lin H; Wright JD; Gross CP; Boscoe FP; Hutchison LM; Schwartz PE; Desai VB
J Clin Oncol; 2019 Dec; 37(35):3412-3424. PubMed ID: 31518176
[TBL] [Abstract][Full Text] [Related]
7. Risk of Occult Uterine Sarcoma in Women Undergoing Hysterectomy for Benign Indications.
Kho KA; Lin K; Hechanova M; Richardson DL
Obstet Gynecol; 2016 Mar; 127(3):468-473. PubMed ID: 26855091
[TBL] [Abstract][Full Text] [Related]
8. Unexpected gynecologic malignancy diagnosed after hysterectomy performed for benign indications.
Mahnert N; Morgan D; Campbell D; Johnston C; As-Sanie S
Obstet Gynecol; 2015 Feb; 125(2):397-405. PubMed ID: 25569001
[TBL] [Abstract][Full Text] [Related]
9. Social determinants of access to minimally invasive hysterectomy: reevaluating the relationship between race and route of hysterectomy for benign disease.
Price JT; Zimmerman LD; Koelper NC; Sammel MD; Lee S; Butts SF
Am J Obstet Gynecol; 2017 Nov; 217(5):572.e1-572.e10. PubMed ID: 28784416
[TBL] [Abstract][Full Text] [Related]
10. Uterine Sarcomas in Patients Undergoing Surgery for Presumed Leiomyomas: 10 Years' Experience.
Paul PG; Rengaraj V; Das T; Garg R; Thomas M; Khurd AS
J Minim Invasive Gynecol; 2016; 23(3):384-9. PubMed ID: 26677821
[TBL] [Abstract][Full Text] [Related]
11. Prediction of Occult Uterine Sarcoma before Hysterectomy for Women with Leiomyoma or Abnormal Bleeding.
Lentz SE; Zaritsky E; Tucker LY; Lee C; Lazo IM; Niihara A; Yamamoto M; Raine-Bennett T
J Minim Invasive Gynecol; 2020; 27(4):930-937.e1. PubMed ID: 31352067
[TBL] [Abstract][Full Text] [Related]
12. Endometrial Sampling for Preoperative Diagnosis of Uterine Leiomyosarcoma.
Kho RM; Desai VB; Schwartz PE; Wright JD; Gross CP; Hutchison LM; Boscoe FP; Lin H; Xu X
J Minim Invasive Gynecol; 2022 Jan; 29(1):119-127. PubMed ID: 34265441
[TBL] [Abstract][Full Text] [Related]
13. Occult Leiomyosarcomas in a Canadian Province: A Retrospective Cohort Study.
Wu CQ; Woo LY; Giede KC; Thiel J; Karreman E; Rattray DD
J Obstet Gynaecol Can; 2019 Jan; 41(1):46-51. PubMed ID: 30341020
[TBL] [Abstract][Full Text] [Related]
14. Occult Uterine Sarcoma and Leiomyosarcoma: Incidence of and Survival Associated With Morcellation.
Raine-Bennett T; Tucker LY; Zaritsky E; Littell RD; Palen T; Neugebauer R; Axtell A; Schultze PM; Kronbach DW; Embry-Schubert J; Sundang A; Bischoff K; Compton-Phillips AL; Lentz SE
Obstet Gynecol; 2016 Jan; 127(1):29-39. PubMed ID: 26646120
[TBL] [Abstract][Full Text] [Related]
15. Hysterectomy-Corrected Uterine Corpus Cancer Incidence Trends and Differences in Relative Survival Reveal Racial Disparities and Rising Rates of Nonendometrioid Cancers.
Clarke MA; Devesa SS; Harvey SV; Wentzensen N
J Clin Oncol; 2019 Aug; 37(22):1895-1908. PubMed ID: 31116674
[TBL] [Abstract][Full Text] [Related]
16. Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma.
Parker WH; Fu YS; Berek JS
Obstet Gynecol; 1994 Mar; 83(3):414-8. PubMed ID: 8127535
[TBL] [Abstract][Full Text] [Related]
17. Risk of unanticipated abnormal gynecologic pathology at the time of hysterectomy for uterovaginal prolapse.
Frick AC; Walters MD; Larkin KS; Barber MD
Am J Obstet Gynecol; 2010 May; 202(5):507.e1-4. PubMed ID: 20452498
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of undiagnosed uterine leiomyosarcoma in women undergoing hysterectomy or myomectomy for benign indications.
Lange S; Pluchino N; Fehlmann A; Marci R; Boukrid M; Jazia IB; Petignat P; Dubuisson J
Eur J Obstet Gynecol Reprod Biol; 2017 Sep; 216():239-244. PubMed ID: 28743407
[TBL] [Abstract][Full Text] [Related]
19. State-level uterine corpus cancer incidence rates corrected for hysterectomy prevalence, 2004 to 2008.
Siegel RL; Devesa SS; Cokkinides V; Ma J; Jemal A
Cancer Epidemiol Biomarkers Prev; 2013 Jan; 22(1):25-31. PubMed ID: 23125334
[TBL] [Abstract][Full Text] [Related]
20. Undiagnosed Uterine Sarcomas Identified During Surgery for Presumed Leiomyoma at a National Tertiary Hospital in Thailand: A 10-Year Review.
Ruengkhachorn I; Phithakwatchara N; Nawapun K; Hanamornroongruang S
Int J Gynecol Cancer; 2017 Jun; 27(5):973-978. PubMed ID: 28498251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
